Cochrane · systematic review · CD004759
Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
Hill, P, Cross, NB, Barnett, ANR, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 7.7%Low 9 · 69.2%Moderate 3 · 23.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: kidney transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (including CNI) | RR 0.75 [0.27, 2.06] | 5 studies · 632 participants | Low Downgraded: risk of bias |
All‐cause graft loss (including CNI) | RR 0.65 [0.36, 1.19] | 3 studies · 549 participants | Low Downgraded: risk of bias |
Delayed graft function | RR 0.93 [0.78, 1.1] | 9 studies · 1304 participants | Low Downgraded: risk of bias |
Acute rejection (including CNI) | RR 0.61 [0.49, 0.76] | 12 studies · 1491 participants | Moderate Downgraded: risk of bias |
Infection: CMV infection | RR 1.55 [1.24, 1.95] | 6 studies · 1072 participants | Moderate Downgraded: risk of bias |
Malignancy | RR 0.94 [0.3, 2.94] | 7 studies · 891 participants | Low Downgraded: risk of bias |
Comparison
Population: kidney transplant recipients
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death (ESW both arms) | RR 0.27 [0.07, 1.06] | 3 studies · 180 participants | Low Downgraded: risk of bias |
All‐cause graft loss (ESW both arms) | RR 0.6 [0.34, 1.08] | 4 studies · 360 participants | Low Downgraded: risk of bias |
Acute rejection (ESW both arms) | RR 0.57 [0.35, 0.93] | 4 studies · 360 participants | Moderate Downgraded: risk of bias |
Biopsy‐proven CAN (ESW with alemtuzumab only) | RR 2.45 [1.02, 5.94] | 2 studies · 86 participants | Low Downgraded: risk of bias |
CMV infection (all studies) | RR 1.08 [0.46, 2.56] | 3 studies · 225 participants | Low Downgraded: risk of bias |
NODAT (ESW alemtuzumab only) | RR 0.41 [0.12, 1.4] | 2 studies · 69 participants | Low Downgraded: risk of bias |
Malignancy (all studies) | RR 4.93 [0.59, 41.11] | 3 studies · 187 participants | Very low Downgraded: risk of bias |